MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 1,100 Shares of Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) insider Kristian Reich sold 1,100 shares of the business’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $20.00, for a total value of $22,000.00. Following the sale, the insider directly owned 2,711,198 shares of the company’s stock, valued at approximately $54,223,960. This trade represents a 0.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kristian Reich also recently made the following trade(s):

• On Tuesday, July 21st, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $20.02, for a total value of $1,001,000.00.
• On Monday, July 20th, Kristian Reich sold 43,700 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.09, for a total value of $877,933.00.
• On Wednesday, June 17th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $19.43, for a total transaction of $971,500.00.
• On Monday, June 15th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.89, for a total transaction of $944,500.00.

MoonLake Immunotherapeutics Trading Down 1.9%

NASDAQ MLTX traded down $0.35 during mid-day trading on Wednesday, hitting $18.36. The company’s stock had a trading volume of 707,747 shares, compared to its average volume of 1,488,842. The firm has a market capitalization of $1.35 billion, a P/E ratio of -4.74 and a beta of 1.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75. The stock’s fifty day simple moving average is $19.08 and its two-hundred day simple moving average is $17.81.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Research analysts expect that MoonLake Immunotherapeutics will post -3.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MLTX. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, July 20th. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. Leerink Partners boosted their price objective on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Finally, Needham & Company LLC upped their target price on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $24.21.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MLTX. Kestra Advisory Services LLC acquired a new stake in MoonLake Immunotherapeutics during the 4th quarter valued at approximately $26,000. EverSource Wealth Advisors LLC raised its position in shares of MoonLake Immunotherapeutics by 221.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock valued at $53,000 after purchasing an additional 1,974 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter valued at approximately $58,000. Russell Investments Group Ltd. boosted its stake in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at approximately $47,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.